New additions to antibody panels in the characterisation of chronic lymphoproliferative disorders

Academic Department of Haematology and Cytogenetics, The Royal Marsden Hospital and Institute of Cancer Research, Fulham Road, London SW3 6JJ, UK.
Journal of Clinical Pathology (Impact Factor: 2.92). 04/2002; 55(3):180-3. DOI: 10.1136/jcp.55.3.180
Source: PubMed


Advances in flow cytometry techniques and the availability of monoclonal antibodies that detect key functional molecules on lymphocytes have contributed greatly to a more precise diagnosis of the chronic lymphoproliferative disorders. In addition to the diagnostic value, the expression of certain markers such as p53 or CD38 provides relevant prognostic information to the clinician. Beyond their diagnostic and prognostic value, immunological markers play a major role in the detection of minimal residual disease, enabling the clinician to estimate more accurately the response to chemotherapy. Those monoclonal antibodies that are relevant to the characterisation of the chronic lymphoproliferative disorders and that could be incorporated in a routine practice are discussed.

Download full-text


Available from: Estela Matutes, Jul 23, 2014
5 Reads
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Objectives: To report the experience and the importance of flow cytometry immunophenotyping by measuring the positivity and antigenic expression intensity in the diagnosis of 48 patients with hairy cell leukemia (HCL). Methods: From November 1991 to June 2005, 4318 cases were analyzed by flow cytometry, 3556 (82.3%) of which were oncohematological diseases. Forty-eight cases of hairy cell leukemia (1.3%) were diagnosed. Morphological analysis was performed on slides stained with Grunwald Giemsa panchromatic dye, analyzed by two experienced professionals. The cytochemical analyses made were for acid phosphatase and tartrate-resistant acid phosphatase (TRAP). For antigenic expression analysis, the monoclonal antibodies used were: CD2, CD3, CD5, CD7, CD10, CD11c, CD19, CD20, CD22, CD23, CD25, CD38, HLA-DR, FMC-7, CD79b, CD103, IgM, IgG, IGD, kappa and lambda. results: By analyzing positivity and monoclonal antibody expression intensity in the forward scatter vs. side scatter histograms (used between 1991 and 2001), and in CD19 vs. SSC histograms with sequential histograms (after 2001), it was possible to confirm this pathology and to discriminate residual cells after the specific therapy. Conclusion: Diagnostic confirmation of hairy cell leukemia by flow cytometry is a fast and accurate method that is useful in the clinical laboratory. The option for an initial CD19 vs. SSC histogram and an analysis of antigenic expression intensity in the bone marrow showed to be statistically more efficient.
  • Source
    Molecular Biology in Cellular Pathology, 08/2003: pages 61 - 78; , ISBN: 9780470867945
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Summary The in-situ polymerase chain reaction (in-situ PCR) is a novel molecular technique that combines the extreme sensitivity of the PCR with the anatomical localization provided by in-situ hybridization. A number of groups have recently reported studies using in-situ PCR for the detection of specifically amplified single-copy nucleic acid sequences in single cell preparations or low copy DNA sequences in tissue sections. In this overview, we describe the principles of in-situ PCR, review the applications of this technique and discuss future aspects of in-situ PCR. We critically compare the different in-situ PCR protocols described in the literature. Emphasis is placed on the absolute requirement for controls to allow accurate interpretation of results and the possible problems and pitfalls of the in-situ PCR methods, in-cluding artefacts related to diffusion of PCR products and non-specific incorporation of labelled nucleotides into fragmented DNA undergoing repair. It is concluded that this technique will eventually play an important role in specialized diagnostic laboratories in the evaluation of viral diseases, haematological and other malignancies which have unique genetic markers.
    Molecular Biology in Cellular Pathology, 08/2003: pages 233 - 250; , ISBN: 9780470867945
Show more